AURKA and hepatocellular carcinoma: In our investigation, we assessed the impact of the Aurora-A kinase inhibitor Alisertib alongside Donafenib on HCC, focusing on the mechanisms that facilitate their synergistic induction of ferroptosis in the HCCLM3 and Huh7 cells, as well as in subcutaneous xenograft models.